PDCD1 and non-small cell lung carcinoma: A meta-analysis has also demonstrated that anti-PD-1/anti-PD-L1 monotherapy is highly effective in male patients but not in female patients, even in NSCLC with high PD-L1 expression levels (Conforti et al., 2021).